Programme (updated March 6)
IOF-ECCEO12 CONGRESS - BORDEAUX 2012
Day 3 - Friday, March 23
Venue |
 Palais des Congrès de Bordeaux |
|
|---|---|---|
| 9.00 - 11.50 |
Scientific Session III
Chaipersons: B. Masri - T. Schaeverbeke - M.L. Brandi |
AMPHI A |
| 9.00 - 9.30 |
Plenary Lecture 4
Current controversies in primary and secondary fracture prevention - E. McCloskey
|
AMPHI A |
| 9.30 - 9.50 |
Oral Communications selected from abstracts
|
AMPHI A |
| 9.50 - 10.00 |
Presentation of the IOF Medal of Achievement
|
AMPHI A |
| 10.00 - 10.30 |
Plenary Lecture 5
How long should we treat? - C. Roux
|
AMPHI A |
| 10.30 - 11.40 |
Oral Communications selected from abstracts
|
AMPHI A |
| 11.40 - 11.50 |
Presentation of the IOF Pierre D. Delmas Award
|
AMPHI A |
| 12.15 - 13.45 |
Pfizer Lunch Symposium
Breaking New Ground: Exploring the Role of Third-Generation SERMs
Chair: C. Christiansen
• Weighing Your Options: Review of Latest Clinical Findings in Bisphosphonates and SERMs - P. Hadji
• Selecting the Right SERM: Review of Differences - S. Ferrari
• Individualized Approach to Postmenopausal Osteoporosis Treatment - J. Calaf y Alsina
• Panel Question & Answer Session/Closing Remarks
|
AMPHI B |
| 12.15 - 13.45 |
ESCEO Symposium
Diagnosis and treatment of osteoarthritis: state of the art
Chaipersons: J.-Y. Reginster - F. Berenbaum
• Osteoarthritis in Europe: a major health burden - N. Arden
• Diagnosis and follow up of the disease - H. Genant
• Benefits and limitations of osteoarthritis treatments - J.-P. Pelletier
• Challenges of drug development in osteoarthritis - R. Chapurlat
• New perspectives in the management of osteoarthritis - C. Cooper
|
AMPHI A |
| 13.45 - 15.00 |
Poster Session 2
|
POSTERS |
| 14.00 - 15.00 |
Oral presentation of selected posters
|
MAIN HALL |
| 14.00 - 15.00 |
Meet-The-Expert Sessions
Clinical utility of bone turnover markers - E. Cavalier
|
ROOM D1 |
| 14.00 - 15.00 |
Sarcopenia and physical frailty: assessment and management
- Y. Rolland |
ROOM D2 |
| 14.00 - 15.00 |
Avascular necrosis - T. Thomas
|
ROOM H1 |
| 14.00 - 15.00 |
Obesity and fracture risk - J. Compston
|
ROOM H2 |
| 14.00 - 15.00 |
ESCEO-FROMO Symposium
How to define responders in osteoarthritis?
Chaipersons: T. Bardin - O. Bruyère
• Welcome – O. Bruyère
• Natural history and prognosis of lower limbs osteoarthritis
– C. Cooper • Assessment of response rate to structure and symptom modifying therapy in osteoarthritis – J.-P. Pelletier • Novel perspectives in the definition of responders in trials of osteoarthritis – O. Bruyère • Discussion – panel • Wrap-up and conclusions – C. Cooper The panel is constituted by E. Abadie, R. Adachi, T. Bardin, F. Berenbaum, J. Branco, O. Bruyère, C. Cooper, W. Dere, H. Jonsson, J.A. Kanis, A. Laslop, W. Lems, J. Martel-Pelletier, J.P. Pelletier, J.-Y. Reginster, S. Reiter, R.Rizzoli, L. Rovati, Y. Tsouderos |
ROOM E |
| 15.00 - 16.50 |
Scientific Session IV
Chaipersons: C. Roux - E. McCloskey |
AMPHI A |
| 15.00 - 15.30 |
Plenary Lecture 6
Risk-benefits of osteoporosis treatment: lessons from cohort or randomized controlled studies - B. Abrahamsen
|
AMPHI A |
| 15.30 - 16.50 |
Oral Communications selected from abstracts
|
AMPHI A |
| 17.00 - 18.00 |
GREES-ESCEO Symposium
Health Claims for Nutriceuticals Products in the Field of Cartilage and Joint
Chaipersons: O. Bruyère - B. Avouac
• Introduction: challenges and opportunities of health claims in the field of joint and cartilage – B. Avouac
• European regulation of health claims – A. Martin
• Health claims in the field of joint and cartilage:
the recommendations of the GREES – O. Bruyère • Discussion – Panel • Closure of the meeting - O. Bruyère The panel is constituted by B. Avouac, P. Bruel, O. Bruyère, V. Coxam, D. Guillou, J. Guicheux, A.E. Lugrin, E. Maheu, A. Martin, C. Merceron, T. Pauquait, J.-Y. Reginster, P. Richette, Y. Tsouderos, N. Urban, P. Ythier-Moury |
ROOM D |
| 17.00 - 18.30 |
ESCEO-ISPOR Symposium
Compliance with osteoporosis medications : Causes of poor adherence;
current statuts, clinical and economical consequences and interventions
Chaipersons: J. Kanis - M. Hiligsmann
• Welcome and introduction - Mickael Hiligsmann
• Definitions, measures and current status of compliance with osteoporosis medications – F. Gwadry-Sridhar
• Impact of poor adherence on clinical outcomes in osteoporotic patients – J.-Y. Reginster
• The societal burden of poor adherence with osteoporosis médications - O. Ström
• Reasons of poor adherence and interventions to improve patient adherence with osteoporosis medications - E. Manias
• The economic value of improving patient compliance - M. Hiligsmann
• Discussion - Panel
The panel is constituted by F. Gwadry-Sridhar, M. Hiligsmann, J. Kanis, E. Manias, J.-Y. Reginster, O. Ström |
ROOM E |
| 17.00 - 18.30 |
ESCEO-FROMO Symposium
Treatment of osteoporosis in men
Chaipersons: R. Rizzoli - J. Ringe
• Welcome – J.-Y. Reginster
• Osteoporosis in men: is it different from postmenopausal osteoporosis? - C. Cooper
• Pathophysiology of osteoporosis in men - J.-M. Kaufman
• Treatment of male osteoporosis with bisphosphonates
- S. Boonen • Treatment of male osteoporosis with other agents - E. Orwoll • Discussion - Panel • Wrap-up and conclusions - J.-M. Kaufman The panel is constituted by M. Audran, S. Boonen, M.-L. Brandi, A. Chines, C. Cooper, W. Dere, J.P. Devogelaer, A. Diez-Perez, J.A. Kanis, J.-M. Kaufman, S. Korte, A. Laslop, E. Mccloskey, B. Mitlak, E. Orwoll, S. Papapoulos, J.-Y. Reginster, J. Ringe, R. Rizzoli, Y. Tsouderos, G. Weryha |
ROOM F |
